Previous issues

STAY CONNECTED

Number 36 May - June 2010

» [Editorial] When the trial you need is just over the border » [Cover Story] Jaap Verweij: an intelligent approach to drugs » [e-Grand Round] The treatment of gastrointestinal stromal tumours (GIST) » [Cutting Edge] Who’s who in the world of personalised cancer treatments? » [Masterpiece] Blazing a trail in a new type of research » [Impact Factor] Trials and tribulations in primary CNS lymphoma » [Impact Factor] Androgen deprivation therapy for prostate cancer: true love or heartbreak? » [Newsround] Newsround » [Systems & Services] Should you respect a dying wish?

Number 35 March - April 2010

» [Editorial] Stop excluding male patients » [Cover Story] Alain Fourquet: taking multidisciplinarity one step further » [e-Grand Round] Neutropenia in cancer patients: risk factors and management » [Cutting Edge] MRI for breast cancer: who benefits, who is harmed? » [Masterpiece] From unwanted interference to indispensable partner » [Impact Factor] Future directions in multimodality therapy for NSCLC » [Impact Factor] Sunitinib versus interferon-á in metastatic RCC » [Patient Voice] Spreading the word » [Newsround] Newsround

Number 34 January - February 2010

» [Editorial] A Partnership with potential » [Cover Story] Jan Geißler: We, the patients » [e-Grand Round] Indolent prostate cancer and active surveillance » [Cutting Edge] Keyhole surgery » [Best Cancer Reporter Award] Ten years reporting from the front line » [Masterpiece] Specialism: political oncology » [Impact Factor] Adjuvant chemotherapy in older patients with breast cancer » [Impact Factor] PET–CT imaging in non-small-cell lung cancer » [Newsround] Newsround » [Patient Voice] Shall we try for a baby?

Number 33 November - December 2009

» [Editorial] Rare cancers in Europe - tackling a common problem » [Cover Story] Vesna Kesic: exporting excellence in women’s cancers » [e-Grand Round] Addressing fertility issues in patients with breast cancer » [Best Cancer Reporter Award] The ‘no miracle cure’ story » [Masterpiece] The power behind the World Cancer Declaration » [Spotlight on...] Should we expect better from the media? » [Spotlight on...] Addicted to wonder drugs » [Spotlight on...] Mass media’s hit or myth approach to cancer » [Impact Factor] GIST adjuvant therapy - some answers and more questions » [Impact Factor] Role of lymphadenectomy in the staging of endometrial cancer » [Newsround] Newsround

Number 32 September - October 2009

» [Editorial] Talking the same language » [Cover Story] Eric Van Cutsem: closing in on GI tumours » [e-Grand Round] State-of-the-art and controversies in germ-cell cancer » [Drug Watch] Gotta get that rhythm - Circadian timing systems and cancer » [Best Cancer Reporter Award] Are we educating women to be afraid? UK health reporter questions the value of simplistic screening messages » [Masterpiece] Vested interests are undermining our efforts to beat cancer - The worries of a battle-hardened German oncologist » [Impact Factor] Effect of treatment interruptions in prostate cancer » [Impact Factor] Endocrine-therapy-related symptoms and breast cancer » [Newsround] Newsround » [Patient Voice] A man with a woman's cancer How can we do better for male breast cancer patients?

Number 31 July - August 2009

» [Editorial] Prostate cancer screening: a question of common sense » [Cover Story] Michael Gnant: pushing the boundaries » [e-Grand Round] Advanced epithelial ovarian cancer: improvements in first- and second-line treatment » [Drug Watch] Beyond trench warfare American and European researchers in search of a winning strategy » [Masterpiece] Surfing the wave » [Impact Factor] Bortezomib in newly diagnosed multiple myeloma » [Impact Factor] Vaccine trials in melanoma - time for reflection » [Newsround] Newsround » [Systems & Services] EUROCARE 4 delivers its verdict » [Focus] Angiogenesis inhibition: do tumours have a plan B?

Number 30 May - June 2009

» [Editorial] It’s about living not just surviving » [Cover Story] Pat Price: asking the right questions » [e-Grand Round] Decision making for systemic treatment of non-small-cell lung cancer » [Drug Watch] Health rationing in Europe: can cancer get a fair hearing? » [Masterpiece] Closing the gap with the West » [Impact Factor] Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck » [Impact Factor] Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer » [Newsround] Newsround » [Systems & Services] Why are cancer patients still suffering unnecessary pain? » [Focus] Chemobrain: delving into possible mechanisms

Number 29 March - April 2009

» [Editorial] Europe's nurses: an untapped resource » [Cover Story] Emiel Rutgers: a surgeon for the genomic era » [e-Grand Round] New oncoplastic techniques can avoid mastectomy » [Masterpiece] New drug combinations are not the solution: Sweden's screening guru argues early detection is what works in breast cancer » [Spotlight on...] Helping women make the right choices: Europa Donna launches Breast Health Day » [Impact Factor] Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? » [Impact Factor] How does extended lymphadenectomy influence practical care for patients with gastric cancer? » [Newsround] Newsround » [Patient Voice] Emaciated but not unloved Patients and carers need support to cope with the distressing effects of cachexia » [Systems & Services] Europe’s rare cancer community calls for a more radical approach

Number 28 January - February 2009

» [Editorial] Senior, elderly, geriatric: we are all getting older » [Cover Story] Jean-Pierre Droz: We can do better for our older patients » [e-Grand Round] Combining hormonal therapy with local treatment in prostate cancer » [Drug Watch] Oncology’s successes must not fail the heart » [Masterpiece] Siding with the vulnerable » [Best Cancer Reporter Award] Everyone deserves the best chance to survive » [Impact Factor] Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma » [Impact Factor] Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer » [Newsround] Newsround » [Focus] The root of all evil?

CancerWorld invites you to visit:

European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.

Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.

ECPC

Europa
Donna

Europa
Uomo

EONS

SIOG

The
Challenge
Fund

SenoNetwork

CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.

Cancer World